Lantern Pharma to Report First Quarter 2026 Financial Results on May 15

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms. The full press release is available here.

The announcement comes as Lantern continues to advance its clinical pipeline, which includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog). LP-300 is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

Importantly, Lantern recently commercialized withZeta.ai, its multi-agentic AI co-scientist platform, which is now available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, potentially transforming its business model from a pure-play drug developer to also a provider of AI tools for drug discovery. The platform leverages the same technology that underpins Lantern’s internal drug development efforts, offering external researchers access to advanced AI capabilities.

Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s focus on integrating AI and machine learning into oncology drug development positions it at the intersection of two high-growth sectors: precision medicine and artificial intelligence. The upcoming financial report will provide investors with insights into the company’s cash position, burn rate, and progress toward key milestones, which are critical for a clinical-stage biotech firm.

For investors, the first-quarter results will offer a glimpse into the financial health of the company and the potential impact of the withZeta.ai subscription revenue. As Lantern continues to advance its clinical programs and expand its AI platform, the May 15 report could serve as a catalyst for the stock, depending on the operational updates provided. The company’s ability to execute on its clinical trials and generate revenue from its AI platform will be key factors to watch.